In a recent strategic progress update, NewGenIvf Group Limited (NASDAQ: NIVF) has witnessed a notable surge in its stock price. As of the latest market check, NIVF shares have climbed 24.65%, trading at $1.05 on the US stock charts.
- Advancing The Proposed Reverse Merger
- Details Of The Proposed Transaction
Advancing The Proposed Reverse Merger
NewGenIvf (NIVF) has announced ongoing active evaluations of the proposed reverse merger with COVIRIX Medical Pty Ltd. In order to meet the requirements needed for the Proposed Transaction to close, both firms have thoroughly investigated each other's businesses and are still making great progress in that direction.
By the end of August 2024, the firms want to have the non-binding term sheet completed for this deal. During the due diligence phase, COVIRIX disclosed that its treasury holds a crypto asset of substantial market value, nearly equivalent to NewGenIvf's current market capitalization. This asset has the potential to provide significant financing support for COVIRIX's drug development program.
Concurrently, NewGenIvf has secured a contract with a channel dealer to order a substantial volume of IVF treatments and surrogacy services through the end of 2025. This contract signifies a strong vote of confidence in NewGenIvf's capabilities and underscores the company's commitment to maximizing shareholder value through strategic opportunities, including the proposed COVIRIX reverse merger.
Details Of The Proposed Transaction
According to the Term Sheet, NewGenIvf proposes to issue 102,890,000 of its ordinary shares to the shareholders of COVIRIX or their nominees in exchange for a 100% equity interest in COVIRIX, at an implied price of US$6 per share, amounting to a total of US$617,340,000.
Concurrently, COVIRIX intends to raise US$6 million at the same share price for NIVF, in a form agreeable to both parties. Upon stockholder approval of the Proposed Transaction, COVIRIX shareholders are anticipated to hold approximately 85.8% equity interest in NewGenIvf. Additional details regarding the Proposed Transaction will be announced once a definitive agreement is executed.
新生IVF Group Limited (納斯達克：NIVF) 最近發佈了戰略進展公告，該公司股票價格出現了顯著飆升。截至最新市場檢查，NIVF股票上漲了24.65%，在美國股票圖表上交易價格爲$1.05。
推進擬議的反向合併
NewGenIvf (NIVF) 已宣佈正在積極評估與COVIRIX Medical Pty Ltd的擬議反向合併。爲了達成擬議交易的要求，兩家公司已經彼此深入調查對方的業務，並且在這個方向上仍在取得良好的進展。
截至2024年8月底，兩家公司希望完成關於該交易的非約束性條款。在盡職調查階段，COVIRIX披露其庫存有一個大市值（幾乎等同於NewGenIvf當前市值）的加密資產，這個資產有潛力爲COVIRIX的藥品開發計劃提供重要的融資支持。
同時，NewGenIvf已與渠道經銷商簽署合同，以訂購大量的IVF治療和代孕服務，該合同標誌着對NewGenIvf能力的強烈信心，並強調了該公司致力於通過戰略機會（包括擬議的COVIRIX反向合併）最大化股東價值。
擬議交易的細節
根據條款表，NewGenIvf擬發行102,890,000股普通股，以每股6美元的含義價格，換取COVIRIX100%的股權，總數爲6.1734億美元，發給COVIRIX股東或其提名人。與此同時，COVIRIX打算以同樣的股價爲NIVF籌集600萬美元，以得到雙方都同意的形式。在股東批准擬議交易之後，預計COVIRIX股東將持有NewGenIvf大約85.8%的股權。一旦簽署了最終協議，將公佈有關擬議交易的其他細節。
同時，COVIRIX打算以同樣的股價爲NIVF籌集600萬美元，以得到雙方都同意的形式。在股東批准擬議交易之後，預計COVIRIX股東將持有NewGenIvf大約85.8%的股權。一旦簽署了最終協議，將公佈有關擬議交易的其他細節。
